191725-73-2

Basic information

• Product Name: 2-(1H-pyrazol-1-yl)propan-1-ol
• Synonyms: 2-(1H-pyrazol-1-yl)propan-1-ol;02(3-Pyrazol-1-yl-phenyl)-methanol;Albb-004087;2-(1H-pyrazol-1-yl)-1-propanol(SALTDATA: FREE);2-(1H-Pyrazol-1-yl)-1-propanol
• CAS NO: 191725-73-2
• Molecular Formula: C6H10N2O
• Molecular Weight: 126.16
• Mol File: 191725-73-2.mol

Chemical Properties

• Boiling Point: 225.2°C at 760 mmHg
• Flash Point: 90°C
• Appearance: /
• Density: 1.12g/cm³
• Vapor Pressure: 0.0499mmHg at 25°C
• Refractive Index: 1.541
• CAS DataBase Reference: 2-(1H-pyrazol-1-yl)propan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1H-pyrazol-1-yl)propan-1-ol(191725-73-2)
• EPA Substance Registry System: 2-(1H-pyrazol-1-yl)propan-1-ol(191725-73-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 191725-73-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(1H-pyrazol-1-ol)propan-1-ol is used as a building block for the synthesis of various drugs and bioactive molecules, leveraging its pyrazole ring structure and propanol side chain to contribute to the development of new pharmaceutical agents.
Used in Organic Synthesis:
Pyrazolol is employed as a reagent in organic synthesis, where its unique chemical properties facilitate the creation of a range of organic compounds for various applications.
Used in Coordination Chemistry:
In coordination chemistry, 2-(1H-pyrazol-1-yl)propan-1-ol is used as a ligand, participating in the formation of coordination compounds that have potential applications in various fields, including catalysis and materials science.
Used in Drug Development:
Pyrazolol has potential applications in drug development, where its properties can be harnessed to design and synthesize new therapeutic agents with improved pharmacological profiles.
Used in Medicinal Chemistry:
As a valuable tool for researchers, pyrazolol is utilized in medicinal chemistry to explore its potential in the discovery and optimization of bioactive molecules for therapeutic use.

InChI:InChI=1/C6H10N2O/c1-6(5-9)8-4-2-3-7-8/h2-4,6,9H,5H2,1H3

Upstream product

• 288-13-1 NH-pyrazole 
• 75-56-9 methyloxirane 

Relevant articles and documents

SMALL MOLECULE MODULATORS OF IL-17

The present invention relates to a compound according to formula (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

Y(NO3)3·6H2O catalyzed regioselective ring opening of epoxides with aliphatic, aromatic, and heteroaromatic amines

Yttrium nitrate hexahydrate [Y(NO3)3·6H2O] was found to be an efficient catalyst for selective ring opening of epoxides with aliphatic, aromatic, and heteroaromatic amines at room temperature under solvent-free conditions. The system tolerated a variety of hindered and functionalized epoxides/amines and afforded the desired β-amino alcohols at low catalyst concentration.

Piperidine and tetrahydropyridine derivatives

A class of substituted piperidine and tetrahydropyridine derivatives, linked through the 4-position thereof via an alkylene chain to a fused bicyclic heteroaromatic moiety such as indolyl, and further substituted at the 1-position by an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl-alkyl, aryl-alkyl or heteroaryl-alkyl moiety, are selective agonists of 5-HT1 -like receptors, being potent agonists of the human 5-HT1Dα; receptor subtype whilst processing at least a 10-fold selective affinity for the 5-HT1Dα; receptor subtype relative to the 5-HT1Dβ; subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.